Engineered vesicles deliver miR-204 to triple-negative breast cancer cells in preclinical tests
Researchers engineered GE11-targeted vesicles that delivered tumor-suppressive miR-204 into EGFR1-positive triple-negative breast cancer cells, inhibiting their growth in lab and ...

